Article Details

AstraZeneca, Daiichi breast cancer drug set for speedy FDA review | BioPharma Dive

Retrieved on: 2022-07-25 13:48:52

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca, Daiichi breast cancer drug set for speedy FDA review | BioPharma Dive. View article details on HISWAI: https://www.biopharmadive.com/news/astrazeneca-daiichi-enhertu-fda-priority-review-her2-low/627985/

Excerpt

AstraZeneca and Daiichi Sankyo are seeking approval of their drug for HER2-low breast cancer that's either spread or can't be removed by surgery, ...

Article found on: www.biopharmadive.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up